Pharmacovigilance Agreements (PVAs) are agreements between two companies based on their Commercial Agreements that require an exchange of safety information between the two companies. PVAs are not stand alone agreements but dependent on the relationships established between two companies regarding at least one medicinal and/or developmental product. The existence of strong PVAs is necessary to support the safety of the product and patient safety globally. PVAs may also be referred to as Safety Data Exchange Agreements by some pharmaceutical companies.
You may also be interested in:
White Paper
Local Representation: What Clinical Trial Sponsors Need to Know
In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major…
Fact Sheet
Literature Surveillance: Important Information About Patient Safety
Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their…
Page
Pharmacovigilance & Patient Safety
We provide a comprehensive range of drug safety services, minimizing risk and protecting patient well-being from clinical development to…